PT - JOURNAL ARTICLE AU - Alexander R. Haug AU - Axel Rominger AU - Mona Mustafa AU - Christoph Auernhammer AU - Burkhard Göke AU - Gerwin P. Schmidt AU - Björn Wängler AU - Paul Cumming AU - Peter Bartenstein AU - Marcus Hacker TI - Treatment with Octreotide Does Not Reduce Tumor Uptake of <sup>68</sup>Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors AID - 10.2967/jnumed.111.089276 DP - 2011 Nov 01 TA - Journal of Nuclear Medicine PG - 1679--1683 VI - 52 IP - 11 4099 - http://jnm.snmjournals.org/content/52/11/1679.short 4100 - http://jnm.snmjournals.org/content/52/11/1679.full SO - J Nucl Med2011 Nov 01; 52 AB - We hypothesized that 68Ga-DOTATATE uptake of neuroendocrine tumors is sensitive to therapy with a nonradioactive somatostatin analog. Methods: 68Ga-DOTATATE PET/CT was used to examine 105 patients, 35 of whom had been pretreated with long-acting octreotide. The maximum standardized uptake value (SUVmax) of target tissues, as well as metastases, was compared between the groups of patients with (group 1) and without (group 2) octreotide treatment. Results: The SUVmax of the spleen and liver was significantly lower in group 1 than in group 2 (both P &lt; 0.001). There were no significant group differences in SUVmax for primary tumors (28.6 ± 6.8 vs. 32.9 ± 31.5) or metastases in the liver (27.2 ± 14.8 vs. 25.7 ± 10.7), lymph nodes (41.4 ± 19.5 vs. 25.0 ± 6.3), or skeleton (39.5 ± 22.0 vs. 15.4 ± 7.8). In 9 patients available for intraindividual comparison, tumor uptake was unaffected by treatment with somatostatin analogs (21.7 vs. 20.6; P = 0.93). Conclusion: Treatment with a long-acting somatostatin analog did not significantly reduce 68Ga-DOTATATE binding in neuroendocrine tumors but tended to improve the tumor-to-background ratio.